Sign up
Pharma Capital

Citius Pharmaceuticals unveils favorable pricing of US$10mln secondary offering; shares soar

Proceeds from the stock sale will be used to fund late-stage clinical trials for its drug Mino-Lok, which treats catheter-related bloodstream infections
Scientist with a microscope
The specialty pharmaceutical company develops critical care products

Citius Pharmaceuticals Inc (NASDAQ:CTXR) has unveiled the pricing of a US$10mln secondary share offering.

The Cranford, New Jersey, company intends to use the money to fund its Phase 3 clinical trial for its drug Mino-Lok, which treats catheter-related bloodstream infections. The money will also go towards its Phase 2b trial of its Hydro-Lido cream for the treatment of hemorrhoids as well as working capital.

Investors applauded the move and sent Citius shares up 50% to US$1.71 by the early afternoon.

Citius will offer 7.8mln shares of its stock and an equal amount of warrants. Each share is being sold together with a warrant. One share of stock will be sold at a combined price of US$1.275 per share, as well as the accompanying warrant. 

The warrants can be exercised immediately at a price of US$1.15 per share and expire five years from the date of their issuance.

The offering, which is expected to close on or about August 13, is set to earn US$10mln in proceeds on a gross basis.

HC Wainwright & Co is the book-runner for the offering.

Citius is a specialty pharmaceutical company that develops critical care products.

Contact Ellen Kelleher at [email protected]

Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.